AstraZeneca makes surprise U-turn with £300m pharma investment

AstraZeneca's unexpected investment signals a potential thaw in relations between the pharmaceutical giant and the UK government. This move could be interpreted as a response to improved conditions or incentives offered by the government, aiming to bolster the local pharmaceutical sector. However, it raises questions about the long-term sustainability of such investments if underlying issues related to drug pricing and NHS policies remain unresolved.